The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use  by Manson, Stephanie C. et al.
Respiratory Medicine (2009) 103, 975e994ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedREVIEW
The cumulative burden of oral corticosteroid side
effects and the economic implications of steroid useStephanie C. Manson a,*, Ruth E. Brown a, Annamaria Cerulli b,
Carlos Fernandez Vidaurre ca United BioSource Corporation, 20 Bloomsbury Square, London WCIA 2NS, UK
b Novartis Pharma AG, Basel, Switzerland
c Novartis Pharma AG, East Hanover, NJ, USA
Received 18 June 2008; accepted 5 January 2009
Available online 15 April 2009KEYWORDS
Corticosteroids;
Glucocorticosteroids;
Adverse events;
Asthma;
Economic* Corresponding author. Tel.: þ44 20
E-mail address: stephanie.manson
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.01.003Summary
Oral corticosteroids (OCS) are a key part of therapy regimens for a diverse variety of condi-
tions. Despite their efficacy, they are associated with a wide variety of adverse events. The
purpose of this review was to identify the range of adverse events that have been reported
to be related to oral corticosteroids, examine the factors that influence their incidence and
estimate the economic burden caused by these adverse events. In 61 identified studies, 21
different categories of OCS related adverse events were reported with increased fracture risk
being the category most frequently described. Most studies that examined factors linked to the
incidence of OCS related adverse events found that dose, age, gender, duration of use, treat-
ment history, smoking habits or cholesterol level were influential in determining risk. Addition-
ally, a cumulative economic analysis of selected adverse events found the annual cost of
treating these events in the UK to be at least £165 per patient taking OCS. The clinical and
economic burden of OCS related adverse events highlights the need for OCS sparing therapies
to be developed.
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Since the first isolation of cortisol in 1950, corticosteroids
have proved to be extremely effective in the treatment of
acute inflammation and chronic inflammatory diseases.
However, despite their clinical success, oral corticosteroids
(OCS) are used sparingly due to a broad array of serious
adverse events including bone fractures, osteoporosis,
susceptibility to infections, hyperglycemia, and obesity
amongst others. Although corticosteroids are typically
prescribed for a wide range of patients with inflammatory
conditions, it is most frequently prescribed for patients
with respiratory conditions such as asthma or chronic
obstructive pulmonary disease (COPD), who represent 40%
of patients taking OCS in the UK, with skin diseases (6%),
musculoskeletal conditions (6%) and neurological conditions
(3%) being the next most common conditions being treated
with OCS.1 Despite the associated risks, data show that oral
corticosteroids are used by as many as 0.9% of the adult UK
population at any one time.1 This figure increases with age,
with 2.5% of individuals between the ages of 70 and 79 using
corticosteroids. This has created a strong ongoing need
for steroid-replacement therapy within pharmaceutical
disease management.
Corticosteroids are thought to act by binding with cyto-
solic glucocorticoid receptors which causes a repression in
the transcription of immunologically active genes. To a lesser
extent, they also promote the transcription of anti-inflam-
matory genes, which are thought to be responsible for many
of the adverse events associated with corticosteroids.2
There are many different ways of administering OCS
therapy, all of which can influence the occurrence of
adverse events. Firstly, there are several different drugs in
the OCS family, with prednisolone and its pro-drug predni-
sone, being the most commonly prescribed.1 Other OCS
therapies are hydrocortisone, cortisone, methylprednisone,
dexamethasone, triamcinolone, betamethasone, budeso-
nide, fluocortolone and deflazacort. These often have niche
applications in treating specific conditions. The duration of
OCS treatment can vary significantly depending on the
condition being treated and the patient response to treat-
ment. For example, some asthma attacks can be efficientlymanaged with a short burst of OCS therapy3 whereas some
patients with Crohn’s disease are dependent on long term
OCS therapy in order to prevent disease exacerbation.4
Different doses can also alter the risk of adverse events5
and even when treatment with OCS is completed, risk for
adverse events can linger,6 making it difficult to assess the
risk factors associated with OCS. Because most studies
focus on either a single adverse event related to OCS
treatment or adverse events in a specific population, there
is a need for an overall understanding of the generalised
risks conferred by OCS therapy across all patients.
While OCS adverse events can be severe and require
resource-intensive treatment, the potentially large
economic implications have not been examined. This is
particularly relevant for measuring the economic value of
steroid-sparing therapies in comparison to OCS therapy.
Furthermore, since many studies only identify pre-selected
adverse events which are not indicative of the broad
spectrum of adverse advents known to be OCS-associated,
it is not possible to use these studies to estimate the
economic impact of OCS adverse events as a whole, hence
the value of this review.
As the multi-faceted negative consequences of OCS
therapyarebecomingbetter understood, thedrive tofindOCS
substitutes becomesmoreurgent. In some conditions, inhaled
corticosteroids have replacedOCSandhavebeen successful in
reducing the incidence of adverse events due to less systemic
exposure, but the same diverse profile of adverse events
remains.7 Steroid avoidance has become a key focus in the
effective management of patients treated with OCS, leading
to the development of many non-steroidal drugs that have
comparable anti-inflammatory action.8 However, in order to
appreciate the value of these drugs, the wide picture of OCS
adverse events must be considered in order to determine the
real cost offsets achievable by these therapies.
Methods
Search strategy
A literature search of key databases including MEDLINE,
EMBASE and Cochrane Library was performed to identify
30%
11%
32%
16%
11%
a
b
c
d
e
Figure 1 Study quality distribution.
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treatment. Search terms included commonly used cortico-
steroids, i.e. prednisone, prednisolone, methylprednisilone,
betamethasone and dexamethasone and adverse events
common to corticosteroids such as myocardial infarction,
hypertension, adrenal insufficiency and osteoporosis. The
search covered the period January 1990eMarch 2007. A full
illustration of the search canbe found inAppendix I. All initial
search hits identified were assessed for relevancy. Full
papers were obtained for studies that appeared potentially
relevant and were formally reviewed. Additional papers
identified from the reference lists were also included.
Inclusion and exclusion criteria
Papers were considered relevant if they measured the
prevalence of OCS adverse effects among oral steroid users,
the relationship between the presence of OCS side effects
and patient characteristics such as treatment history, age,
gender, or duration of steroid use, the doseeresponse
relationship, the threshold effect related to the dose of the
corticosteroid or the presence of OCS side effects in cost-
effectiveness models.
Papers were excluded if they only studied inhaled
corticosteroids, or corticosteroids administered systemi-
cally/IV, were conducted in an infant population, did not
examine adverse events due to OCS, examined adverse
events that did not have direct clinical consequences (e.g.
reduction in bone mineral density is a laboratory observa-
tion without direct consequences while osteoporosis or
fracture are clinical events requiring specific treatment) or
were not published in the English language. OCS studies
that did not report adverse events or reported them as not
being relevant were not included. Commentaries, letters,
descriptive narratives and unpublished conference
abstracts were also excluded.
Data extraction strategy
To guide the extraction of relevant data a standard data
extraction form was developed. This form included: study
objective; study design, population and setting; main
outcome(s) measured; relevant results and adverse events
reported; and study conclusions. Studies were entered in
date order and categorised according to four primary study
objectives: (1) the prevalence of OCS adverse effects among
oral steroid users; (2) the relationship between the presence
of OCS side effects and patient characteristics such as
treatment history, age, gender, or duration of steroid use; (3)
the doseeresponse relationship, or threshold effect related
to the dose of the corticosteroid; and (4) the presence of OCS
side effects in cost-effectiveness models.
If statistical significance was identified in a study, then
only significant results were reported. The results were
based on published data only, and authors were not con-
tacted for clarification of trial reports.
Study quality evaluation
In order to assess the quality and strength of the papers,
several criteria were graded on a scale of 0e2 on criteriaput forward by Hailey and colleagues, as is detailed in
Table 2. A score of 2 indicated full execution and detail of
a specific criteria, 1 indicated partial consideration was
given and 0 indicated that information was not available or
the criteria was not met.
The total numerical score was then summed in order to
assign the study a total quality grade of AeE, with A cor-
responding with a score of 9 or 10 out of 10 total points, B
with 7 or 8 points, C with 5 or 6 points, D with 3 or 4 points
and E with 1 or 2 points.9 Studies rated A, B or C were
considered to be of reasonable quality and studies rated D
and E were considered to be substandard. The distribution
of study quality can be seen in Fig. 1.
Cost analysis
An economic analysis was performed to estimate the
additional economic burden caused by AEs directly related
to OCS. For clinically discreet AEs-fracture, cataract, dia-
betes, peptic ulcer, stroke, myocardial infarction and non-
Hodgkin’s lymphoma- that had a reported relative risk (RR),
the baseline incidence of these AEs was subtracted in order
to identify the number of AEs that occurred as a direct
result of OCS treatment (e.g. if the relative rate of an AE
was 1.95 relative to controls, the rate of additional AE
instances due to OCS treatment was 1.95e1.00Z 0.95).
This was then multiplied by the overall population inci-
dence rate to determine the additional number of AEs
caused uniquely by OCS in patients receiving treatment.
Because the studies used to identify RR values were quality
studies (AeC) with reasonable numbers of OCS patients
(range 539e404,183), no correction factor was applied RR
values. The cost per AE episode or cost per year of AE
treatment was applied in order to calculate the economic
burden per OCS treated individual for these particular AEs.
This was done from a UK perspective using UK cost data
wherever possible and using the incidence data of the UK
population for all AEs. When more than one study reported
the RR of an AE, the RR from the study with the largest
patient population was used.
Results
A total of 246 abstracts were identified. Of these, a total of
117 articles were retrieved and upon review, 63 documents
were included in this literature review. A summary of
rationale for exclusion can be found in Table 1.
Table 2 Study performance classification criteria (Hailey
et al., 2004).
Areas of interest Points considered
Patient selection Methods of randomisation/
selection; equivalence of
intervention and control
groups; drop-outs before start of
intervention
Description/specification
of the interventions
Adequate description for both
intervention and control groups
Specification and
analysis of study
Sample size; statistical methods
used; clear specification of
outcome measures
Patient disposal Length of follow-up; drop-outs;
compliance failures
Outcomes reported Fullness and clarity of reporting;
missing results; statistical
summary; whether conclusions
were consistent with data
978 S.C. Manson et al.Of the 63 documents included, 28 studies were retro-
spective reviews of medical records, 15 were prospective
non-randomised trials, 10 were small randomised
controlled trials (<50 patients per arm), 5 were large
randomised controlled trials, 2 were meta-analyses, 1 was
an economic analysis and 1 was a review paper.
All 63 studies reported adverse events related to therapy
with OCS. A total of 1,221,575 unique patients on OCS
treatment were included, with an average of 21,062 (range
8e404,183) patients per study, after accounting for studies
that were conducted on the same patient population (but
not accounting for unique analyses done using different
patient selection criteria from the same database). A total
of 14 studies (22%) had no placebo or control arms. These
studies identified a wide range of OCS adverse events in
a large variety of patient groups, confirming the broad
spectrum of risk conferred by treatment with OCS.
Incidence of adverse events
Many studies included all patients treated with OCS
regardless of primary diagnosis. The distribution of primary
diagnosis of patient populations included in the studies is
detailed in Table 3. Asthma patients were the most
commonly studied group, followed by chronic obstructive
pulmonary disease (COPD) patients.
Likewise, a wide variety of adverse events were attrib-
uted to OCS, with fractures being the most frequently cited
followed by gastric conditions (Table 4). A complete
synthesis of the occurrence of OCS related adverse events
for all studies can be found in Table 5. All identified studies
are included in this table regardless of OCS dose, treatment
duration, patient population and presence of an appro-
priate control group. Due to the great heterogeneity of
these studies, no attempt has been made to further
synthesize these results in order to determine a represen-
tative mean increased risk.
Paediatric adverse events
Because a child’s body is still developing and growing, OCS
can cause a different profile of side effects compared to
adults.10 To examine this difference, studies that focused
on children were isolated, and it was found that while
several adverse events in children are common to theTable 1 Exclusion criteria.
Reason for exclusion Total
Non-English paper 11
Did not meet eligibility criteria (i.e. age) 5
Specific adverse events not examined 55
Adverse events not clinically significant 23
Focus on non-oral corticosteroids 39
Focus on combined therapies 9
Focus on drug therapies to alleviate OCS
side effects (i.e. bisphosphonates)
26
Focus of study not related to side effects
due to use of oral corticosteroids
14
Total excluded 184general adult population, impaired growth was uniquely
reported in children and adolescents (Table 6). These
differences were confirmed in a further study that
compared the rate of OCS adverse events in vitiligo patients
age 15 or younger (nZ 38) and those older than 15
(nZ 43).11 Of the 13 different adverse events identified,
facial swelling, weight gain and acne occurred significantly
more frequently in adults than in youths and abdominal
pain occurred more frequently in youths (p< 0.05 for all).
Doseeresponse relationship
Several epidemiological studies have examined the dosee
response relationship of oral corticosteroids, particularly in
relation to fractures.12e17,5,18,19,1 In these studies of all
forms of OCS treatment, the highest doses (considered
approx. >7e15 mg/day prednisolone equivalent) were
universally found to be associated with the largest inci-
dence of fractures, which were located in the hip, verte-
brae or elsewhere in the body. Although the incidence of
fractures generally increased with dose throughout the
studies, there were a few isolated cases where the
observed incidence of fractures was slightly lower in an
intermediate dose compared to the low dose (i.e. Van Staa
et al. 2000,71 forearm fracture; Van Staa et al. 200520
osteoporitic fracture following low previous cumulative
exposure). Additionally, de Vries and colleagues reported
that patients with an intermediate dose had the highest risk
of fractures. Apart from these anomalies, risk of fracture in
adults with a higher dose increased between 41%1 and
920%5 compared to low dose OCS fracture incidence. This
effect was also observed in children, who demonstrated
a 20% increase in fracture risk at high dose, but only
minimal differences were present between incidence of
fracture at low and middle doses.16
Although doseeresponse relationship was most frequently
reported in relation to fractures, several other adverse events
were observed to have a doseeresponse relationship
including diabetes/hyperglycemia,21 cataracts,5 ocular
hypertension,22 open-angle glaucoma,22 bruising,5 muscular
Table 3 Summary of patient populations studied.
Primary diagnosis # Of studies (# of
quality studies)a
Primary diagnosis # Of studies (# of quality
studies)a
Mixedb 22 (20) Hormone-refractory prostate cancer 2 (0)
Asthma 8 (4) Skin disease 1 (1)
COPD 6 (4) Osteoporosis 1 (1)
Ocular condition 5 (3) Cardiovascular disease 1 (1)
Arthritis 3 (3) Polymyalgia rheumatica 1 (1)
Inflammatory bowel disease 3 (3) Nephrotic syndrome 1 (1)
Lupus 3 (2) Toxic ingestion 1 (1)
Childhood thrombocytopenic
purpura
3 (1) Alcoholic hepatitis 1 (1)
Skin disease allergic rhinitis 3 (0) Vitiligo 1 (0)
a Quality studies are defined as those having an A, B or C grade on a scale of AeE.
b Studies enrolled all available patients taking OCS regardless of diagnosis.
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events.26 Once more, the majority of studies demonstrated
increasing incidence of adverse events with increased dose,
with increases as high as 1034% in hyperglycemia for patients
with very high OCS doses.21 Taken together, the results
overwhelmingly support the relationship between increased
incidence of adverse events and high doses of OCS. Although
the risk of adverse events is somewhat mitigated by lower
doses, patients with low doses still exhibit a nearly universal
enhanced risk for OCS related AEs.
Because the majority of these studies indiscriminately
included all OCS users, it was not possible to assess whether
the doseeresponse relationship varied according to specific
OCS therapies.
Relationship between OCS adverse events and
duration of use, treatment history, age and gender
There are many variables besides dose that can dictate the
extent and severity of adverse events suffered by patients
taking oral corticosteroids. The most commonly identified
factor was duration of use, with seven studies examining the
relationship between cumulative previous dose and adverse
events.24,27,20,26,14,16,22 In a patient survey of eight commonTable 4 Summary of adverse events associated with OCS use.
Adverse event # Of studies (# of quality
studies)
Fracture 28 (24)
Gastric condition 13 (9)
Psychiatric condition 11 (4)
Skin condition 8 (6)
Hyperglycaemia 8 (5)
Weight gain 7 (5)
Ocular condition 6 (5)
Cerebrovascular 6 (4)
Cardiac condition 5 (3)
Infection 4 (4)
Moon face 4 (3)
Abnormal hair growth 4 (2)
Quality studies are defined as those having an A, B or C grade on a scAEs related to OCS (bone fractures, high blood sugar, cata-
racts,mood problems, weight gain, skin-bruising or thinning,
acne and sleeping problems), all AEs were found to be more
severe according to cumulative dose.27 Van Staa and
colleagues examined the risk of fracture and found that the
risk of all types of fractures increase with higher cumulative
dose (1 g c. <1 g). Treatment with OCS for over 90 days,
regardless of cumulative dose, also increased risk signifi-
cantly (p< 0.001).14 Garbe and colleagues found that
increased cumulative OCS dose was related to an increase in
ocular hypertension and acute angle glaucoma. Five
different cumulative doses were examined, with a consis-
tent increase of ocular AEs between the first four doses,
although the highest cumulative dose exhibited a slight
decrease in incidence. Another study24 examined dose
duration without considering cumulative dose and found
that patients were 1.84 times as likely to experience
amyocardial infarctionwith a short dose duration (30 days)
compared to a long dose duration (>31 days). Treatment
history was also important in children who had increased risk
following four or more courses of OCS.16
Other relationships were also reported, such as treat-
ment history,24,25,6,16 age,20,17,18,28 gender,20,6,18,28 treat-
ment pattern,14 smoking habits,17 cholesterol level,29 andAdverse event # Of studies (# of quality
studies)
Pain 4 (1)
Impaired growth 3 (3)
Hypertension 3 (1)
Weakness 3 (1)
Adrenal insufficiency 2 (2)
Respiratory 2 (0)
Non-Hodgkin lymphoma 1 (1)
Deep vein thrombosis 1 (0)
Wound dehiscence 1 (0)
Urinary disorder 1 (0)
Menstrual disorder 1 (0)
ale of AeE.
Table 5 Summary of all studies identifying OCS related adverse events.
Study first
authorref
Year Study
quality
(AeE)
OCS name OCS therapy
length
Primary diagnosis # Of
patients
Patient incidence of adverse event Placebo incidence
de Vries12 2007 A n/a n/a n/a 191,752 60% increase in osteopathic fracture
(<7.5 mg/day); 115% increase in 7.5e
15 mg/day;> 30 mg/day 363% increase
No control group
14 studies have no
control group
de Vries55 2007 A OCS (prednisolone,
dexamethasone,
traimcinolone,
hydrocortisone)
>4 months Inflammatory disease 6763 Femur/hip fracture increased (crude OR
1.66, 95% CI: 1.46e1.90)
n/a
Varas-Lorenzo24 2007 A Prednisolone or
equivalent
Current use
within last 30
days, recent
use 30e180
days prior, past
use >180 days
n/a 4795 Increased risk of myocardial infarction
(adjusted RRZ 1.71 [95% CI 1.44e2.02]
for current users, adjusted RRZ 1.44 [95%
CI 1.34e1.83] for recent users, adjusted
RRZ 1.28 [95% CI 1.15e1.43] for past
users
n/a
Curtis27 2006 B Prednisone,
prednisolone,
dexamethasone,
other OCS
>60 days n/a 2446 Weight gain (70%); 1 AE e Weight gain,
cataracts, fractures, acne, skin-bruising
(90%); also found association between
greater cumulative dose and increased AEs
n/a
Huiart25 2006 A n/a n/a COPD 371 Increased risk of Acute myocardial
infarction (adjusted RRZ 2.01 [95% CI
1.13e3.58]) for patients w current OCS
exposure, patients w past exposure also
at increased risk (adjusted RRZ 2.01 [95%
CI 0.90e1.70)
n/a
Mortimer56 2006 C n/a 90 days Asthma; COPD 154 Increased risk of adrenal insufficiency
OR 2.0 (95% CI 1.6e2.5) per course of
treatment per year
n/a
Syed57 2006 B n/a n/a Osteoporosis 37 Refractures 37.8% (RR 1.84 vs. control) 20.6%
Donnan6 2005 A n/a n/a n/a 20,266 Higher risk of fracture (RRZ 1.90, 95% CI
1.68, 2.16); 1 in 6 vertebral and 1 in 13
non-vertebral fractures attributed to OCS;
women at higher fracture risk than men
(RRZ 5.19 [95% CI 2.15e9.16]
n/a
Kumagai29 2005 D Prednisone or
equivalent
>1 month Autoimmune disease 160 Patients w hyperlipidemia
(cholesterol> 280 mg/dl) have higher
risk for vertebral fracture (RRZ 3.1,
pZ 0.032)
No control group
Nagasawa58 2005 C Prednisolone 5 years Systemic lupus
erythematosus
45 Osteonecrosis of femoral head 15 (33%)
silent ONF; 5 (11%) symptomatic ONF
n/a
van Staa20 2005 A n/a n/a n/a 191,752 7412 osteoporotic fracture (RR 1.21,
95% CI 1.04e1.42); increased RR in
older patients and women
n/a
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Vestergaard13 2005 A Prednisolone or
equivalent
n/a Fracture 124,655 Increased risk of fracture present with
>2.5 mg/day, RR increases with dose
n/a
Patel59 2000 D Prednisolone n/a Polymorphic light
eruption (PLE)
10 GI upset (1); depressed mood (1) 0
Sorensen32 2004 A n/a n/a n/a 59,043 non-Hodgkin lymphoma (standardized
incidence ratio SIRZ 1.30), pZ 0.04
n/a
Souverein26 2004 B OCS (cortisone,
hydrocortisone,
prednisone,
prednisolone,
triamcinolone,
methylprednisone,
dexamethasone,
betamethasone)
n/a Ischemic heart disease 50,656 Increased risk of any cardiovascular or
cerebrovascular outcome (adjusted OR
1.25, 95% confidence interval (CI) 1.21e
1.29); increased risk of heart failure
(adjusted OR 2.66, 95% CI 2.46e2.87); risk
of heart failure is highest with current use
versus recent (adjusted ORZ 1.40) or past
use (adjusted ORZ 1.19)
n/a
Steinbuch14 2004 A n/a >2 years n/a 17,957 Fractures (relative risk and 95% CI): hip
1.87 (95% CI, 1.2e2.9); vertebral 2.92 (95%
CI, 2.0e4.3); wrist/forearm 1.03 (95% CI,
0.8e1.4); non-vertebral 1.68 (95% CI, 1.5e
1.9); any fracture 1.75 (95% CI, 1.6e1.9);
for all fractures considered together,
significant increase in risk (p< 0.001) for
increased dose, duration and treatment
pattern (continuous versus sporadic)
n/a
van der Voort60 2004 C n/a n/a n/a 1680 Osteoporosis risk of 71% in women using
OCS
39% Osteoporosis
risk
Van Staa15 2003 C Prednisone
equivalent
1 year Rheumatic, pulmonary
and skin disorders
195 57 Multiple fractures, daily prednisone
equivalent dose >15 mg/day increases
risk (RRZ 1.62)
39 Multiple
fractures
Van Staa16 2003 A Prednisolone 6.4 days
(mean)
n/a 37,562 In children only e Fracture 22,846;
increased risk for children taking 30 mg
(RRZ 1.24) and children with 4 courses
of OCS (RRZ 1.32)
14716
Blackburn33 2002 A n/a n/a n/a 31,864 Diabetes 906 626 (inhaled CS
users); 1065
(proton pump
inhibitor users)
Joly61 2002 D Prednisone n/a Bullous Pemphigoid 171 11 Patients had pneumonia, 7 acquired
diabetes, 6 had cardiac failure, 4 had
psychiatric symptoms, 4 experiences
stroke, 6 had deep vein thrombosis,
3 had bone fracture
8 patients had
pneumonia, 2
acquired diabetes,
7 had cardiac
failure, 4
experienced
stroke, 4 had deep
vein thrombosis, 3
had bone fracture
(continued on next page)
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Table 5 (continued)
Study first
authorref
Year Study
quality
(AeE)
OCS name OCS therapy
length
Primary diagnosis # Of
patients
Patient incidence of adverse event Placebo incidence
Lazenby62 2002 C Prednisone 1 week Asthma 20 Increased oesophageal acid - pH< 4.0
at distal probe was 5.9%G 0.9%, at
proximal probe 0.8%G 0.2%
pH< 4.0 at distal
probe
2.5%G 0.4%;
proximal probe
0.3%G 0.1%
Maltais63 2002 C Prednisolone 10 days COPD 62 Hyperglycaemia 7 (10%) 0 (0%)
Simon51 2002 C Prednisone n/a Juvenile idiopathic
arthritis
24 Impaired growth e Mean final height
was 2.0G 1.8 expressed as the
height standard deviation score for
chronological age
No control group
van Everdingen64 2002 B Prednisone 2 years Rheumatoid arthritis 41 Mean body weight increase from
77 19 kg to 80 20 kg (pZ 0.001)
Osteoporotic fractures (8); peptic
symptoms (7)
No weight gain,
Osteoporotic
fractures (4);
peptic symptoms
(3)
Van Staa65 2002 C Prednisolone 5.4 years n/a 2,891 Increased fractures meta-analysis n/a
Walsh17 2002 D Prednisolone n/a Chronic lung disease 117 58% had osteoporosis (a T score <2.5);
61% had a vertebral fracture, strong
relationship between dose and vertebral
fracture (RRZ 4.4 between highest and
lowest dose quartiles), also relationship
between vertebral fractures, age and
smoking status
n/a
Levine66 2002 C Budesonide,
prednisone
n/a Juvenile Crohn’s disease 120 Hirsutisum (1/62); moon face (2/62); acne
(1/62); herpetic infection (2/58); proximal
myopathy (1/58); depression (5/58)
Marcocci67 2001 C Prednisone 5 months Graves’ ophthalmopathy 41 Any OCS adverse AE 35 (85%) e
consisting of urinary tract infection,
glucose intolerance, cushingoid features
n/a
Oinuma68 2001 D n/a 12 months Systemic lupus
erythematosus
72 Osteonecrosis 32 (44%) No control group
Van Staa18 2001 A Prednisolone 7.4 months n/a 244,235 Excess hip fractures (females; >85 y) were
1.4 cases per 100 patients per year. 47%
hip and 72% vertebral fractures could be
attributed to oral corticosteroid use.
Among 10,000 females, 99.7 nonvertebral,
31.6 hip and 45.8 vertebral fractures can
be attributed to oral corticosteroids.
Increased risk associated with high dose
plus female sex
n/a
982
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Walsh5 2001 A Prednisolone 6.4 years (F);
4.5 years (M)
Asthma; COPD; Fibrosing
Alveolitis
367 Cataracts (18.4%); oral candidiasis
(29.7%); use of H2-antagonists/
indigestion (22.6%); bruising (72.9%);
muscle weakness (60%); height loss of
>2.5 cm since age 25 (37.6%); back pain
(54%); osteoporotic fracture (23.2%); 2 or
more fractures (7.4%); Increased rate of
all fractures, cataracts, bruising and
muscle weakness fracture with higher
cumulative dose
Cataracts (8.6%);
oral candidiasis
(2.7%); use of H2-
antagonists/
indigestion (7.8%);
bruising (10.9%);
muscle weakness
(19.3%); height
loss of >2.5 cm
since age 25
(26.3%); back pain
(48.2%);
osteoporotic
fracture (14.7%); 2
or more fractures
(3.1%)
Nishimura69 2000 E Dexamethasone n/a Hormone-refractory
prostate carcinoma
37 Hypertension (2); mental confusion (2);
cataracts (1); diabetes (1)
No control group
Rothberg28 2000 B n/a n/a n/a 1614 Hip fractures (1 F; 3 M); osteoporosis
(14.1% F; 5.9% M) RRZ 1.45; Women
older than 45 yrs e 17.6% osteoporosis,
0.2% hip fracture; female gender and old
age predictor of increased osteoporosis
Women older than
45 yrs e 12.9%
osteoporosis, 0.5%
hip fracture
Van Staa70 2000 A n/a 28 days
(median)
n/a 244,235 Nonvertebral fracture RRZ 1.33;
forearm fracture RRZ 1.09; hip fracture
RRZ 1.61; vertebral fracture RRZ 2.60;
all fractures exhibited a dose dependant
relationship
n/a
Van Staa71 2000 A n/a n/a n/a 244,235 Nonvertebral fracture RRZ 1.33 (95%
confidence interval [CI], 1.29e1.38); hip
fracture RRZ 1.61 (1.47e1.76); forearm
fracture RRZ 1.09 (1.01e1.17); vertebral
fracture RRZ 2.60 (2.31e2.92); fractures
exhibited a dose dependant relationship
n/a
Zonana-Nacach19 2000 C Prednisone >2 months Systemic lupus
erythematosus
539 Osteoporotic fractures (relative risk [RR]
2.5, 95% confidence interval [95% CI] 1.7,
3.7), symptomatic coronary artery disease
(RR 1.7, 95% CI 1.1, 2.5), and cataracts (RR
1.9, 95% CI 1.4, 2.5); 1.2-fold increase in
avascular necrosis (95% CI 1.1, 1.4) and
stroke (95% CI 1.0, 1.5); increase in risk
with each additional two month exposure
n/a
(continued on next page)
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Table 5 (continued)
Study first
authorref
Year Study
quality
(AeE)
OCS name OCS therapy
length
Primary diagnosis # Of
patients
Patient incidence of adverse event Placebo incidence
Kim11 1999 E Prednisolone 4 m Vitiligo 81 Patients experienced several OCS AEs
including facial swelling (21%), weight gain
(17.3%), acneiform eruption (9.9%),
weight gain (4.9%), gastrointestinal
disorders (6.2%), abdominal pain (4.9%),
hypertrichosis (3.7%) and insomnia (2.5%);
differences in AE incidence between
paediatric and adult population
no control group
Dasgupta72 1998 C Prednisolone 96 weeks Polymyalgia rheumatica 25 Bruising 4 (13.3%); dyspepsia 3 (9.9%);
Chest infections 4 (13.3%); urinary tract
infections 1 (3.3%); ankle oedema 3
(9.9%); moon face 3 (9.9%); tremor 1
(3.3%); depression1 (3.3%); hypertension 2
(6.6%); back pain 2 (6.6%); cataract 2
(6.6%); fractures 8 (26.6%)
n/a
Sartor73 1998 E Prednisone n/a Hormone-refractory
prostate cancer
29 Myopathy (4); diabetes (1); dyspnoea (1) No control group
Sharma74 1998 E Prednisolone;
betamethasone
>3 months Alopecia areata 16 Hyper-acidity (1); headache (1);
transient giddiness (1); body ache (1)
No control group
Borgna-Pignatti75 1997 E Dexamethasone 6 months Chronic idiopathic
thrombocytopenia
purpura
17 Fatigue (9); irritability (7); abdominal
pain (2); phobias, headache, anxiety,
striae rebrae, hirsutism and acne (all 1)
No control group
Campieri76 1997 C Prednisolone (pred);
budesonide (bud)
12 weeks Crohn’s disease 177 During study: moon face - prednisolone
group 22/58, budesonide groups (both
once and twice daily) 15/119; acne e pred
11/58, bud 23/119; swollen ankles e pred
3/58, bud 7/119; bruising e pred 7/58,
bud 17/119; hirsutism e pred 3/58 bud
6/119; buffalo hump e pred 2/58, bud
0/119; others e pred 16/58, bud 13/119
No control group
Garbe22 1997 A OCS (hydrocortisone,
cortisone,
prednisone,
prednisolone,
triamcinolone,
dexamethasone,
betamethasone)
n/a Ophthalmology patients 9793 Ocular hypertension (crude OR 1.43,
adjusted OR 1.41); risk increases with
longer duration of OCS use and
increased dose
n/a
Ginsberg77 1996 D dexamethasone 48 h Iohexol myelography 42 Insomnia (1); dyspepsia (1) 0
Howland78 1996 C Prednisone 6 weeks Allergic rhinitis 16 Adrenocortical function - mean
change in 6-hour plasma cortisol
levels 33.38 mg/dl (p< 0.001)
49.81 mg/dl
984
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Naber79 1996 D Methylprednisolone;
fluocortolone
8 days Ocular diseases 50 36% organic mood disorder, 26e34%
hypomanic syndrome, 10e12% a
depressive syndrome
no control group
Ziv80 1996 B prednisone >1 month Ulcerative colitis 361 Septic surgical complications 2 of 10
(20%) low dose; 5 of 10 (50%) high dose
1 of 26 (3.8%)
Scarfone81 1995 D Prednisone Single dose Asthma 55 Vomiting pill 10 (15%) 0 (0%)
Allen52 1994 C Prednisone; ‘other
oral’
n/a (meta-
analysis)
Asthma 810 Prednisone growth impairment
(ZZ 2.137, pZ 0.0164, mean rZ
0.295); ‘other oral corticosteroids’
(ZZ 9.107, pZ 2.44E-18, mean rZ -
0.260)
n/a
Blanchette82 1994 D Prednisone 21 days Childhood acute immune
thrombocytopenic
purpura
39 Weight gain 6% of pre-trial weight n/a
Decramer23 1994 E Methylprednisolone
(17); prednisone (3);
triamcinolone (1)
>6 months COPD; asthma 21 Peripheral muscular weakness 8, greater
muscle weakness positively correlated
with log of average daily dose
no control group
Gurwitz21 1994 A OCS (cortisone,
hydrocortisone,
prednisone,
prednisolone,
triamcinolone,
methylprednisolone,
dexamethasone,
betamethasone)
n/a n/a 11,855 Estimated relative risk for hyperglycemia
requiring treatment was 2.23 (95% CI,
1.92e2.59) as compared with nonusers
n/a
Saag83 1994 A Prednisone >1 year Rheumatoid arthritis 112 Fracture 21; serious infections 14;
gastrointestinal bleed or ulcer 11;
cataracts 17
Fracture 8; serious
infections 4;
gastrointestinal
bleed or ulcer 4;
cataracts 5
Blanchette84 1993 C Prednisone 21 days Childhood acute immune
thrombocytopenic
purpura
18 Mean 3.6% weight gain of pre-trial
weight; 1 incidence of each: glycosuria,
epigastric discomfort, behavioural change
0
Chrousos85 1993 C Prednisone 14 days Optic neuritis 155 Sleep disturbance 70 (45%); mild mood
change 53 (34%); stomach upset
64 (41%); facial flushing 16 (10%)
Sleep disturbance
30 (20%); mild
mood change 24
(16%); stomach
upset 37 (25%);
facial flushing 3
(2%)
Olgaard86 1992 C Prednisone;
deflazacort
6 and 12
months
Nephrotic syndrome 29 Forearm bone decay rate 5.3%/year (PDN)
and 2.0%/year (DFZ). Mandible decay rate
7.0%/year (both groups); lumbar spine
12.5%/year (PDN) and 6.8%/year (DFZ).
No control group
(continued on next page)
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Table 5 (continued)
Study first
authorref
Year Study
quality
(AeE)
OCS name OCS therapy
length
Primary diagnosis # Of
patients
Patient incidence of adverse event Placebo incidence
Ramond87 1992 C Prednisolone 28 days Severe alcoholic
hepatitis
32 Psychological disturbance (1);
bacterial meningitis (1)
Bacterial infection
(1);
gastrointestinal
bleeding (1)
Sanders88 1992 D Prednisone primarily n/a Asthma 240 Hypertension (associated with OCS
withdrawal) 9
no control group
Fechner89 1991 E Prednisone Single dose Corneoscleral wounds 100 Wound dehiscence requiring resuturing
10 (10%)
0
Piper30 1991 B Cortisone;
hydrocortisone;
prednisolone;
prednisone;
meprednisone;
triacinolone;
paramethasone
acetate;
dexamethasone;
betamethasone
n/a Gastric/duodenal ulcer;
upper gastrointestinal
haemorrhage
1,415 Peptic ulcer RRZ 2.0 (95% CI, 1.3 to
3.0). Risk increased in concurrent
NSAID/corticosteroid use to 4.4 (CI,
2.0e9.7). RR for corticosteroid users not
receiving NSAIDs was 1.1 (CI, 0.5e2.1).
n/a
Anderson90 1990 C Prednisone;
prednisolone
3 weeks
(tapered 14e21
days)
Corrosive oesophageal
injury
31 Brain abscess requiring open drainage 1 0
986
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Table 6 Adverse events associated with OCS use in children.
First authorref Year Primary diagnosis # Of patients Adverse event Patient incidence Control incidence
Van Staa16 2003 n/a 37,562 Fractures 22,846 14,716
Simon51 2002 Juvenile idiopathic
arthritis
24 Impaired growth During OCS therapy,
height stunted
2.7 1.5 st devs;
post-OCS 2.0 1.8
Levine66 2002 Juvenile Crohn’s
disease
120 Hirsutism 1/62 n/a
Moon face 2/62
Acne 1/62
Herpetic infection 2/58
Proximal myopathy 1/58
Depression 5/58
Kim11 1999 Vitiligo 38 Facial swelling 4/38 n/a
Abdominal pain 4/38
Weight gain 3/38
Hypertrichosis et al. 3/38
Sharma74 1998 Alopecia areata 16 Hyper-acidity 1/16 n/a
Headache 1/16
Transient giddiness 1/16
Body ache 1/16
Scarfone81 1995 Asthma 55 Vomiting 10 (15%) 0 (0%)
Allen52 1994 Asthma 810 Impaired growth Prednisone vs. control,
pZ 0.0164; other OCS vs
control, pZ 2.44E-18
Blanchette82 1994 Acute immune
thrombocytopenic
purpura
39 Weight gain 6% 1%, 2%
Blanchette84 1993 Acute immune
thrombocytopenic
purpura
18 Weight gain 3.6% 0
Glycosuria 1 0
Epigastric discomfort 1 0
Behavioural change 1 0
Sanders88 1992 Asthma 240 Hypertension 9 n/a
Cumulative burden of oral corticosteroid side effects and the economic implications 987concomitant drugs.30 Treatment history was defined by
current, recent or past use of OCS, although the exact
definition of recent and past use varied somewhat between
studies. It was reported that recent users are the most
likely to develop fractures compared to current and past
users16 but current users have a higher incidence of frac-
ture compared to past users.6,16 For myocardial infarction,
current use imparted the highest risk (1.71 RR) with
reduced risk for recent users (1.44 RR) and past users (1.28
RR) experiencing a progressively lower level of increased
risk.24 Similar increased risk was reported by Huiart et al.
for myocardial infarction, who found current OCS users at
a relative risk of 2.01 and past users at a risk of 1.24
compared to controls as well as Souverein et al. who
reported a relative risk for heart failure of 2.66 for current
OCS users compared to 1.40 for recent users and 1.19 for
previous users. For ocular hypertension and open-angle
glaucoma, current use led to an odds ratio of 1.41
compared to 1.18 for recent use and 0.92 for past use.22
Age was found to increase incidence of fractures in both
men and women20,14 as well as osteoporosis,28 but this was
particularly prevalent in women, who had a 14 fold increase
in hip fractures between the age ranges of 45e54 and 85þ18
and were also more prone to osteoporosis.28 OCS treatment
was also found to have more adverse effects on women
than men with increased incidence of fractures throughoutthe body in women ranging from 164% (vertebral)-316%
(hip)18 which was independently confirmed by an additional
study of vertebral fractures in women and men.6 Sporadic
treatment was found to impart a reduced risk compared to
continuous treatment (p< 0.001),14 as was cholesterol
levels lower than 280 mg/dl (pZ 0.032),29 and concomitant
aspirin was found to increase the risk of peptic ulcers more
than 15 times nonusers of either drug.29 Smoking (number
of pack years) was the only variable that was found to
reduce the risk of vertebral fracture (RRZ 0.50 for >20
pack years).17
Although the effects of treatment duration, treatment
history, age and gender as well as other variables are
potentially less robust than the doseeresponse relation-
ship, it is clear that these factors play a role in the occur-
rence of many of the adverse events related to OCS.
Economic studies
One study was identified that examined the economic
impact of OCS on osteoporosis and bone fractures as well as
the cost-effectiveness of treating osteoporosis with
biphosphonate therapy.31 Although the cost of fracture
increased considerably with age, the average cost for care
of an OCS related hip fracture was £10,761. The cost was
£1976 for a vertebral fracture and £863 for a forearm
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Figure 2 Cost per Patient Year of OCS Related AEs.
988 S.C. Manson et al.fracture. Not included in these amounts are annual costs
for analgesic drugs and nursing home admission necessi-
tated by these fractures. To date, no other economic
analyses have reported the financial burden for the patient,
the health care system, or society due to other adverse
events associated with OCS use.
Cost analysis
Data on RRs was reported for seven different clinically
discreet AEs; fracture, cataract, diabetes, peptic ulcer,
stroke, myocardial infarction and non-Hodgkin’s
lymphoma.24,6,32,33,19,30 These were used as the basis for
a cost analysis. The incidences of these events in the
general population of the UK were identified34e43 allowing
calculation of the estimated total number of events caused
by OCS. The cost per event or per year of treatment was
then applied44e50 to estimate the annual economic burden
attributable to OCS AEs. For all AEs summed together, thisTable 7 Data informing the cost per AE analysis.
Adverse event Relative risk for
patients taking OCS
Study quality
(AeE) of RR Da
Fracture 1.95 A
Diabetes 2.31 A
Peptic ulcer 2.00 B
Stroke 1.20 C
Cataract 1.90 C
Myocardial Infarction 1.42 A
Non-Hodgkin’s
lymphoma
1.30 Aamounted to £165 per OCS treated patient per year, with
fractures representing the most costly of the 7 AEs (Fig. 2).
A summary of the relative risks, general UK population
incidence and UK costs for these 7 AEs can be found in
Table 7.
The cost of managing the 7 C S-related AEs across the
UK population was estimated using this £165 per patient
cost. Controlling for the incidence of these events within
the untreated population and assuming that 0.9% of the UK
population is receiving OCS treatment at any time,1 this
amounts to 14,444 AEs directly related to OCS therapy.
Estimated related costs are £84.2 million annually. Most of
this expenditure falls upon the NHS and could be prevented
by using OCS sparing medications and clinical practices. In
comparison, the NHS spends approximately £996 million to
treat asthma each year (Asthma UK), which is equivalent to
£162 per adult. Asthma is the condition that was most
frequently reported by studies examined to have OCS
related side effects (nZ 7).
Discussion
Our literature search revealed 63 studies identifying 21
different clinical categories of adverse events in 15
different patient groups, thereby confirming the diverse
nature of adverse events caused by OCS and their impact on
a wide variety of patient groups. Fractures were the most
commonly reported AE and they were also the most costly
of AEs included in our economic analysis, costing an
average of £131 per patient taking OCS per year. Of the
studies identifying doseeresponse, all reported the
maximum risk of AEs with the highest dose of OCS. A rela-
tionship between several other factors such as duration of
use, treatment history, age and gender was also examined
in a few studies, confirming there are many variables that
help define the risk of AEs for individual patients taking
OCS.
One benefit of this review is that it indirectly compared
data on the various factors influencing the risk for adverse
events including dose, gender, age, treatment duration,
medical and treatment history. With the exception of
Souverenin et al. who did not find a clear relationship
between increasing dose and increasing risk of AEs, most
studies agreed that these factors related to enhanced risk
for AEs.ta
UK population
incidence
2007 Cost per
episode/yr
Cost per
patient taking OCS
0.0211 £6,541.12 £131.12
0.0038 £2,519.86 £12.39
0.0012 £10,163.28 £12.11
0.0026 £7,148.33 £3.67
0.0043 £890.67 £3.47
0.0039 £1,369.95 £2.27
0.0002 £8,210.21 £0.41
Total £165.44
Appendix I Embase, Medline and Cochrane
Library Inc. Search Strategies
Search Name: Oral steroids_All pops
Comments: 050407
Save Date: 2007-04-05 15:49:29
Database: Cochrane Library, Inc. <to 2007>
Search Strategy:
——————————————————————————————————
ID Search
#1 MeSH descriptor Asthma explode all trees
#2 (asthma*):ti
#3 (#1 OR #2)
#4 MeSH descriptor Prednisolone explode all trees with
qualifier: ae
#5 MeSH descriptor Prednisone explode all trees with
qualifier: ae
#6 MeSH descriptor Betamethasone explode all trees
#7 MeSH descriptor Dexamethasone explode all trees
with qualifier: ae
#8 (prednisolon* or prednison* or methylprednisolone or
betamethason* or dexamethason*):ti
#9 corticosteroid*:ti
#10 (#4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Administration, Oral explode all
trees
#12 ((oral):ti not ‘‘oral health’’:ti) OR (systemic*:ti near
*cortico*:ti)
#13 (#11 OR #12)
#14 (((oral or systemic) near (cortico* or *steroid*)) or
‘‘OCS’’):ti
#15 ((#10 AND #13) OR #14)
#16 Any MeSH descriptor with qualifier: AE
#17 ((advers* or side* or negativ* or detriment*) next
(outcome* or effect*)):ti
#18 MeSH descriptor Hypertension explode all trees
with qualifier: CI
#19 MeSH descriptor Myocardial Infarction explode all
trees with qualifier: CI
#20 MeSH descriptor Osteoporosis explode all trees with
qualifier: ci
#21 MeSH descriptor Cataract explode all trees with
qualifier: ci
Cumulative burden of oral corticosteroid side effects and the economic implications 989Paediatric patients taking OCS were specifically exam-
ined and besides demonstrating many of the adverse events
present in adults, had the additional burden of impaired
growth51,52 and were more susceptible to certain AEs than
adults,11 therefore suggesting a particularly strong need for
OCS sparing treatments in this population.
Not only do the identified adverse events have a strong
negative impact on the health of patients, but they also
have economic and societal consequences as well. The
analysis performed here indicated that for the 6 C S-
related AEs that had RRs reported in the literature, the
annual cost per patient attributable to that OCS related AE
was estimated at £165. This is certain to be an underesti-
mation of the economic burden, because not all AEs had
sufficient data on relative risk to be included, and in
particular, many of the particularly costly AEs were not
included. For example, in Denmark, the four most costly
illnesses are (in descending order) mental illness, cardio-
vascular disease, digestive system disorders, and musculo-
skeletal disorders.53 OCS is a risk factor for all 4 of these
conditions, but only digestive system disorders (i.e. peptic
ulcers) were included in our cost analysis. Thus, a reduction
in OCS dependence and OCS usage could have a strong
economic impact, greater than our current estimate, by
reducing the health care burden for OCS-managed patients.
Economic impact of OCS adverse events has only been
directly reported for fractures.31 However, while the direct
economic impact of treating other AEs related to OCS
hasn’t been established, it can be inferred through pub-
lished costs of treating these conditions in the general
public. For example, diabetes (RR 2.3133) care added
$10,683 to per person annual health costs in the US
(American Diabetes Society, 2003), and the yearly per
patient cost for non-Hodgkin’s lymphoma (RR 2.6832) was
estimated to be between $4260 and $70,452 depending on
severity.54 Although not all costs for treating other adverse
events associated with OCS will be as excessive as these
(e.g. skin conditions, weight gain and moon face might cost
less) and some adverse events have lower overall incidence
than others, the cumulative cost for treatment of all
potential adverse events is likely to be high. Although the
cost analysis performed here is specific to the UK due to the
availability of data, it would be expected that the cost
implications of OCS use in other Western health care
systems would be comparable, especially given the wide-
spread use of OCS to treat several diseases.
Although only 4 studies included in the analysis were
large prospective clinical trials, a large proportion of
studies (28) were chart reviews with an average 58,620
patients each, thus sufficiently large to identify adverse
events in a more natural setting. A shortcoming is that most
trials identified in the literature investigated the presence
of only a single adverse events or adverse events within the
same categories, with only a few studies (16 out of 63
studies) that could directly compare the incidence of
different types of adverse events in the same population
and with the exact same treatment conditions (i.e. dose,
duration of OCS therapy), making a direct comparison of
incidence somewhat less meaningful.
This review highlights the need for further work in terms
of studies to identify the comprehensive risk of adverse
events in patients taking OCS, and in identifying the costburden that these adverse events represent. It is expected
that these data will further emphasize the need to develop
steroid-replacement therapies which will make it possible
to avoid these burdensome adverse events.
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#22 MeSH descriptor Wound Healing explode all trees
with qualifier: DE
#23 MeSH descriptor Atrial Fibrillation explode all trees
with qualifier: ci
#24 MeSH descriptor Adrenal Insufficiency explode all
trees with qualifier: ci
#25 (#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR
#23 OR #24)
#26 (#15 AND #25)
#27 (#26), from 1990 to 2007
#28 MeSH descriptor Postoperative Complications explode
all trees
#29 (#27 AND NOT #28)
Database: EMBASE <1988 to 2007 Week 13>
Search Strategy:
——————————————————————————————————
1 *Glucocorticoids/ae (1319)
2 exp *Prednisolone/ae (1261)
3 exp *Prednisone/ae (2204)
4 exp *Methylprednisolone Hemisuccinate/ae or exp
*Methylprednisolone/ae (1130)
5 exp *Betamethasone/ae (277)
6 exp *Dexamethasone/ae (1311)
7 or/1e6 (6748)
8 exp administration, oral/or ((oral$ or systemic$)
adj3 $cortico$).ti. (187734)
9 7 and 8 (1335)
10 *Glucocorticoids/po (302)
11 *corticosteroid/po (1345)
12 10 or 11 (1640)
13 8 or 12 (189259)
14 exp *Prednisolone/ae (1261)
15 exp *Prednisone/ae (2204)
16 exp *Methylprednisolone Hemisuccinate/ae or exp
*Methylprednisolone/ae (1130)
17 exp *Betamethasone/ae (277)
18 exp *Dexamethasone/ae (1311)
19 (prednisolon$ or prednison$ or methylprednisolone
or betamethason$ or dexamethason$).ti. (11948)
20 ($cortico$ or $steroid$ or glucocorticoid$).ti. (51163)
21 or/14e20 (64988)
22 13 and 21 (6170)
23 exp *side effect/(13352)
24 exp *hypertension/si (1580)
25 exp *myocardial infarction/si (599)
26 exp *osteoporosis/si (1454)
27 *corticosteroid induced osteoporosis/(163)
28 exp *cataract/si (242)
29 exp *Wound Healing/si (21)
30 exp *atrial fibrillation/si (119)
31 exp *Adrenal Insufficiency/si (111)
32 exp *fractures/si (288)
33 (‘‘steroid-induced’’ or ‘‘steroid induced’’).ti. (468)
34 ((advers$ or side$ or negativ$ or detriment$ or ‘‘long
term’’) adj2 (outcome$ or effect$)).ti. (20213)
35 or/23e34 (37427)
36 22 and 35 (410)
37 9 or 36 (1613)
38 (inhaled not oral$).ti. (6439)
39 37 not 38 (1566)
40 letter.pt. (343547)
41 letter/(351404)
42 editorial.pt. (175487)
43 historical article.pt. (0)
44 case report$.pt. (0)
45 case study/(2916)
46 exp animal/not human/(78072)
47 nonhuman/(2390477)
48 anecdote.pt. (0)
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